This trial is yet another nail in the coffin for warfarin in the treatment of atrial fibrillation (AF). For decades, warfarin was the sole blood thinner proven for stroke prevention in patients with AF. The results of ENGAGE AF demonstrate that yet another blood thinner is at least as good as warfarin, with less complications. Once daily Edoxaban was shown to have less bleeding and lower mortality than warfarin. Stroke rates were similar. Edoxaban is now the 4th agent that has tested favorably against warfarin, joining dabigatran, rivaroxaban and apixaban. It will take time for the agent to be approved by the FDA and to become available to our patients, but the writing is on the wall for warfarin in AF stroke prevention. -Dr. David Sandler, cardiac electrophysiologist newsroom.heart.org/news/new-drug-may-be-as-effective-as-common-blood-thinner-for-stroke-prevention
Posted on: Mon, 25 Nov 2013 15:17:52 +0000
Trending Topics
Recently Viewed Topics
© 2015